Can you explain maybe why these biomarkers are different, and why do you think they matter so much?

You know, I think as our criteria have been, uh, revised over time, the aim has really been to incorporate more patients with different presentations in sort of the diagnostic algorithm.

Or rather, to improve their sensitivity, uh, so that we could diagnose patients earlier, particularly as we've got all this compelling data that early treatment can have short and long-term, uh, consequences for patients and, and improve outcomes.

But I think this is really the first criteria where there have been some efforts to ameliorate this problem of, of misdiagnosis.

I, I hope everybody agrees that it's a problem.

I think-There have been maybe twelve or thirteen studies, they're all imperfect in terms of their methodology, but that have been published since two thousand and nineteen or so that have shown that we do see a significant number of patients who are given a diagnosis of MS in our clinics who, who wind up having something else.

So perhaps in response to that, you know, there were some efforts on the part of the committee to, uh, incorporate some elements in the criteria that could prevent misdiagnosis.

Um, Andy, your response to that?